ATXI
Avenue Therapeutics Inc

5,464
Loading...
Loading...
News
all
press releases
Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Expands By 91.7%
Avenue Therapeutics, Inc. (NASDAQ:ATXI - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 313,400...
Zolmax·1y ago
News Placeholder
More News
News Placeholder
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization...
Globe Newswire·1y ago
News Placeholder
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...
Globe Newswire·1y ago
News Placeholder
Avenue Therapeutics granted extension for Nasdaq compliance
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization...
Globe Newswire·1y ago
News Placeholder
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of...
Globe Newswire·1y ago
News Placeholder
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
-In vivo data supports BAER-101's unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg ( GAERS ) model of absence epilepsy-MIAMI, Feb...
Globe Newswire·2y ago
News Placeholder
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Growth in Short Interest
Avenue Therapeutics, Inc. (NASDAQ:ATXI Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest...
Ticker Report·2y ago
News Placeholder
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization of...
Globe Newswire·2y ago
News Placeholder
Why Avenue Therapeutics Shares Are Getting Hammered
Avenue Therapeutics Inc (NASDAQ: ATXI) shares are trading lower by 31% to $0.24 Friday morning after the company announced it has entered into warrant exercise agreements with existing read more...
Benzinga·2y ago

Latest ATXI News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.